Your browser doesn't support javascript.
loading
Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
Hájek, Roman; Sandecka, Viera; Spicka, Ivan; Raab, Marc; Goldschmidt, Hartmut; Beck, Susanne; Minarík, Jirí; Pavlícek, Petr; Radocha, Jakub; Heindorfer, Adriana; Jelínek, Tomás; Stejskal, Lukás; Brozová, Lucie; Sevcíková, Sabina; Straub, Jan; Pika, Tomás; Pour, Ludek; Maisnar, Vladimír; Seckinger, Anja; Hose, Dirk.
Afiliación
  • Hájek R; Department of Hemato-Oncology, University Hospital, Ostrava, Czech Republic.
  • Sandecka V; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Spicka I; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
  • Raab M; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Goldschmidt H; 1st Department of Medicine, 1st Faculty of Medicine, Charles University and General Hospital in Prague, Praha, Czech Republic.
  • Beck S; Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.
  • Minarík J; Internal Medicine V and National Center for Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany.
  • Pavlícek P; Labor für Myelomforschung, University Clinic Heidelberg, Heidelberg, Germany.
  • Radocha J; Department of Hemato-Oncology, University Hospital, Olomouc, Czech Republic.
  • Heindorfer A; Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Praha, Czech Republic.
  • Jelínek T; 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
  • Stejskal L; Department of Clinical Hematology, Hospital Liberec, Liberec, Czech Republic.
  • Brozová L; Department of Hemato-Oncology, University Hospital, Ostrava, Czech Republic.
  • Sevcíková S; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Straub J; Department of Hematology and Transfusion, Hospital Opava, Opava, Czech Republic.
  • Pika T; Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
  • Pour L; Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic.
  • Maisnar V; Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Seckinger A; 1st Department of Medicine, 1st Faculty of Medicine, Charles University and General Hospital in Prague, Praha, Czech Republic.
  • Hose D; Department of Hemato-Oncology, University Hospital, Olomouc, Czech Republic.
Br J Haematol ; 190(2): 189-197, 2020 07.
Article en En | MEDLINE | ID: mdl-32163180
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Quiescente Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mieloma Múltiple Quiescente Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Br J Haematol Año: 2020 Tipo del documento: Article País de afiliación: República Checa Pais de publicación: Reino Unido